A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Researchers are looking for a better way to treat children who have heart failure with
left ventricular systolic dysfunction (LVSD). Heart failure is a serious condition where
the heart is unable to pump enough blood to meet the body's needs. This can lead to
symptom...
Age: 6 months - 17 years
Gender: All
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
This is a multi-center, prospective, observational study designed to evaluate the impact
of LV myocardial fibrosis extent assessed by CMR on LV reverse remodeling and clinical
outcomes post TEER. The target sample will be up to 125 patients enrolled to achieve 100
ev...
Age: 18 years - 66+
Gender: All
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will
lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent
HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with
...
Age: 18 - 99 years
Gender: All
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left
ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they
have been diagnosed with chronic HF at least 3 months before they start on the study. The
pur...
Age: 18 years - 66+
Gender: All
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
This real-world, international registry aims to evaluate the current experience with
sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease
(ACHD) patients by investigating the prescription patterns, safety, tolerability, and
potential b...
Age: 18 years - 66+
Gender: All
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Age: 40 - 85 years
Gender: All
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the
accuracy of an investigational artificial intelligence (AI) Software as a Medical Device
(SaMD) designed to compute ejection fraction (EF) severity categories based on the
America...
Age: 18 years - 66+
Gender: All
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
The availability of Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) has dramatically altered the management of heart failure (HF) patients, independently of their ejection fraction and glycemic status. A meta-analysis of 57 studies comparing SGLT2-I monotherapy vs. ...
Age: 18 years - 66+
Gender: All
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin
(TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that
accumulates in different organs in the body and can cause damage to the organ. There are
two way...
Age: 18 - 75 years
Gender: All
AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
Study Design:
This is an international, multicenter, observational, non-interventional, prospective,
blinded, single-arm, two-period study, to collect patient utterances that will be
retrospectively analyzed to determine the sensitivity and UPNR of the HearO system...
Age: 22 years - 66+
Gender: All
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by
demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used
for the treatment of advanced, refractory, left ventricular heart failure.
Age: 18 - 100 years
Gender: All
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level
of care to the right patients at the right time. It represents an adaption of the Mount
Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care.
T...
Age: 18 years - 66+
Gender: All
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
This is a prospective, multi-center, open label, randomized control clinical trial
evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in
NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial).
The study contains of 5 arms:
...
Age: 18 years - 66+
Gender: All
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Aortix is a circulatory support device for chronic heart failure patients on medical
management who have been hospitalized for acute decompensated heart failure (ADHF) and
have persistent congestion despite usual medical therapy.
Eligible ADHF patients with diureti...
Age: 21 years - 66+
Gender: All
Left vs Left Randomized Clinical Trial
The investigators aim to prospectively test the comparative effectiveness of His or Left
bundle branch pacing in relation to patient centered outcomes (quality of life, physical
activity, heart failure hospitalization, mortality) and comparative safety in relation to
...
Age: 18 years - 66+
Gender: All
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
This registry evaluates patient characteristics, real-world treatment patterns, and
short- and long-term outcomes in a population of patients in the United States and Europe
with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are receiving
mavacamten, ...
Age: 18 years - 66+
Gender: All
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
The REVERSE-HF study is a randomized controlled trial to evaluate clinical outcomes of
adjustable ultrafiltration with the Aquadex System as compared to adjustable IV loop
diuretics in patients with worsening heart failure (HF) and fluid overload.
Age: 18 years - 66+
Gender: All
His-Bundle Corrective Pacing in Heart Failure
The investigators aim to prospectively evaluate the efficacy and mechanism of benefit of
His-bundle pacing enhanced cardiac resynchronization therapy (His-CRT) vs. cardiac
resynchronization therapy (BIV-CRT) in patients with heart failure and right bundle
branch bloc...
Age: 18 years - 66+
Gender: All
ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEF
The overall hypothesis is that treatment with the SGLT2 inhibitor Ertugliflozin induces a differential regulation in interstitial fluid vs plasma volume, with more reduction of the volume from the interstitial fluid than from the circulating plasma volume, which results...
Age: 18 years - 66+
Gender: All
Comparative Effectiveness of Telemedicine in Primary Care
Leveraging a natural experiment approach, the investigators will examine rapidly changing
telemedicine and in-person models of care during and after the COVID-19 crisis to determine
whether certain patients could safely choose to continue telemedicine or
telemedic...
Age: 19 years - 66+
Gender: All